Bisphosphonates: New indications and methods of administration

Current Opinion in Rheumatology

Volumn 15, Issue 4, 2003, Pages 458-463

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alendronate; Cancer; Osteoporosis; Risedronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CONFIDENCE INTERVAL; FRACTURE; HUMAN; HYPERTROPHY; MYELOFIBROSIS; NONHUMAN; OSTEOARTHROPATHY; OSTEOPOROSIS; PRIORITY JOURNAL; REDUCTION; REVIEW;

ALENDRONATE; ANIMALS; DIPHOSPHONATES; ETIDRONIC ACID; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038095264     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200307000-00014     Document Type: Review

References (48)

1. Frijlink WB, te Velde J, Bijvoet OLM, et al.: Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet 1979, i:799-803.
2. Reid IR, King AR, Alexander CJ, et al.: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988, i:143-146.
3. Van Beek ER, Lowik CWGM, Papapoulos SE: Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002, 30:64-70.
4. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al.: Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61:1255-1262.
5. Fromigue O, Body JJ: Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002, 25:539-546.
6. Viereck V, Emons G, Lauck V, et al.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680-686.
7. Boivin G, Meunier PJ: Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002, 43:535-537.
8. Borah B, Dufresne TE, Chmielewski PA, et al.: Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002, 17:1139-1147.
9. Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281-289.
10. Cranney A, Wells G, Willan A, et al.: Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Rev 2002, 23:508-516.
11. Cranney A, Tugwell P, Adachi J, et al.: Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Rev 2002, 23:517-523.
12. Cranney A, Guyatt G, Krolicki N, et al.: A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001, 12:140-151.
13. Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
14. Cranney A, Guyatt G, Griffith L, et al.: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Rev 2002, 23:570-578. This article summarizes the Cochrane collaboration meta-analyses on the treatment of osteoporosis. As such, it provides a valuable overview of the entire trial literature.
15. Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. Although this is not a study of bisphosphonates, it is a landmark study that has already profoundly influenced the management of osteoporosis, in addition to all other indications for which HRT may be considered.
16. Levis S, Quandt SA, Thompson D, et al.: Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002, 50:409-415.
17. Heaney RP, Zizic TM, Fogelman I, et al.: Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002, 13:501-505.
18. Greenspan SL, Schneider DL, McClung MR, et al.: Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 136:742-746.
19. Bell NH, Bilezikian JP, Bone HG, et al.: Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002, 87:2792-2797.
20. Kushida K, Shiraki M, Nakamura T, et al.: The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res Clin Exp 2002, 63:606-620.
21. Greenspan SL, Emkey RD, Bone HG, et al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002, 137:875-883.
22. McClung M, Wasnich R, Omizo M, et al.: Resolution of effect following alendronate: six-year results from the Early Postmenopausal Interventional Cohort (EPIC) Study. J Bone Miner Res 2002, 17(suppl 1):s134.
23. Storm T, Thamsborg G, Steiniche T, et al.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. N Engl J Med 1990, 322:1265-1271.
24. Watts NB, Harris ST, Genant HK, et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
25. Greenspan SL, Bone G, Schnitzer TJ, et al.: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988-1996.
26. Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111.
27. Lanza F, Sahba B, Schwartz H, et al.: The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002, 97:58-64.
28. Greenspan S, Field-Munves E, Tonino R, et al.: Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002, 77:1044-1052.
29. Heijckmann AC, Juttmann JR, Wolffenbuttel BHR: Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 2002, 60:315-319.
30. Ninkovic M, Love S, Tom BDM, et al.: Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002, 37:93-100.
31. Henderson RC, Lark RK, Kecskemethy HH, et al.: Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002, 141:644-651.
32. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661. This phase II study raises the possibility that annual administration of bisphosphonates may be effective in the management of osteoporosis.
33. Taggart H, Bolognese MA, Lindsay R, et al.: Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262-270.
34. Rothschild BM, Helbling M: Is coadministration of alendronate and nonsteroidal antiinflammatory drugs an unacceptable risk? J Clin Rheumatol 2002, 8:288-290.
35. Donahue JG, Chan KA, Andrade SE, et al.: Gastric and duodenal safety of daily alendronate. Arch Int Med 2002, 162:936-942.
36. Thomson ABR, Marshall JK, Hunt RH, et al.: 14 Day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002, 29:1965-1974.
37. Menssen HD, Sakalova A, Fontana A, et al.: Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002, 20:2353-2359.
38. Wood J, Bonjean K, Ruetz S, et al.: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
39. Powles T, Paterson S, Kanis JA, et al.: Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224. This study demonstrates an effect of bisphosphonate administration on survival in patients with breast cancer, which is a significant, novel finding.
40. Rauch F, Travers R, Plotkin H, et al.: The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002, 110:1293-1299.
41. Zacharin M, Bateman J: Pamidronate treatment of osteogenesis imperfecta: lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002, 15:163-174.
42. Parker CR, Blackwell PJ, Fairbairn KJ, et al.: Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 2002, 87:4482-4489.
43. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.
44. Haibel H, Braun J, Maksymowych WP: Bisphosphonates: targeting bone in the treatment of spondyloarthritis. Clin Exp Rheumatol 2002, 20:S162-S166.
45. Eggelmeijer F, Papapoulos SE, Vanpaassen HC, et al.: Increased bone mass with pamidronate treatment in rheumatoid arthritis: results of a three-year randomized, double-blind trial. Arthritis Rheum 1996, 39:396-402.
46. Iwase M, Kim KJ, Kobayashi Y, et al.: A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles. J Orthopaed Res 2002, 20:499-505.
47. Garske LA, Bell SC: Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 2002, 121:1363-1364.
48. Froom P, Elmalah I, Braester A, et al.: Clodronate in myelofibrosis: a case report. Am J Med Sci 2002, 323:115-116.